Gatifloxacin is a racemic compound of 8-methoxyfluoroquinolone. It has a broad spectrum of activity against Gram-negative and positive microorganisms in vitro, and its R- and S-enantiomer antibacterial activities are the same. The antibacterial effect of this product is to inhibit bacterial DNA gyrase and topoisomerase IV, thereby inhibiting bacterial DNA replication, transcription and repair processes.

Market Analysis and Insights: Global Gatifloxacin Market
The global Gatifloxacin market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Gatifloxacin Scope and Market Size
The global Gatifloxacin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gatifloxacin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Tablet
Aqueous Solution
Capsule
Others

Segment by Application
Synthetic Antibacterial
Ophthalmic Medicine
Other

The Gatifloxacin market is analysed and market size information is provided by regions (countries). Segment by Application, the Gatifloxacin market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Pacific Pharma
Apotex
Sandoz
Allergan
Bristol-Myers Squibb
Mylan
Hi Tech Pharmacal
Lupin Pharmaceuticals
Teva Pharmaceuticals